Dyslipidemia and Dementia: Current Epidemiology, Genetic Evidence, and Mechanisms Behind the Associations
Open accessThe DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Abstract
The role of cholesterol in the etiology of Alzheimer's disease (AD) is still controversial. Some studies exploring the association between lipids and/or lipid lowering treatment and AD indicate a harmful effect of dyslipidemia and a beneficial effect of statin therapy on AD risk. The findings are supported by genetic linkage and association studies that have clearly identified several genes involved in cholesterol metabolism or transport as AD susceptibility genes, including apolipoprotein E, apolipoprotein J, and the sortilin-related receptor. Functional cell biology studies support a critical involvement of lipid raft cholesterol in the modulation of amyloid-β protein precursor (AβPP) processing by β- and γ-secretase resulting in altered amyloid-β production. Contradictory evidence comes from epidemiological studies showing no or controversial association between dyslipidemia and AD risk. Additionally, cell biology studies suggest that there is little exchange between circulating and brain cholesterol, that increased membrane cholesterol is protective by inhibiting loss of membrane integrity through amyloid cytotoxicity, and that cellular cholesterol inhibits co-localization of BACE1 and AβPP in non-raft membrane domains, thereby increasing generation of plasmin, an amyloid-β-degrading enzyme. The aim of this review is to summarize the findings of epidemiological and cell biological studies to elucidate the role of cholesterol in AD etiology.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Shepherd, J., Blauw, G. J., Murphy, M. B., Bollen, E. L., Buckley, B. M., Cobbe, S. M., Ford, I., Gaw, A., Hyland, M., Jukema, J. W., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)11600-x · Cited by 3,378
Harold, D., Abraham, R., Hollingworth, P., Sims, R., Gerrish, A., Hamshere, M. L., Pahwa, J. S., Moskvina, V., Dowzell, K., Williams, A., et al. (2009) · Nature Genetics · doi:10.1038/ng.440 · Cited by 3,326 · cited 1×
“org) [72, 73].”
Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease
the European Alzheimer's Disease Initiative Investigators, Lambert, J.-C., Heath, S., Even, G., Campion, D., Sleegers, K., Hiltunen, M., Combarros, O., Zelenika, D., Bullido, M. J., et al. (2009) · Nature Genetics · doi:10.1038/ng.439 · Cited by 2,234
CNS synaptogenesis promoted by glia-derived cholesterol
Mauch, D. H., Nägler, K., Schumacher, S., Göritz, C., Müller, E.-C., Otto, A., & Pfrieger, F. W. (2001) · Science · doi:10.1126/science.294.5545.1354 · Cited by 1,711 · cited 1×
“neuronal compartment.[59,60] In addition, APOE act as a pathological chaperone of Aβ, promoting its fibril formation from soluble Aβ by binding interaction between carboxyterminal domain of apoE and residues 12–28 of full-length Aβ.”
Kivipelto, M., Helkala, E.-L., Laakso, M. P., Hänninen, T., Hallikainen, M., Alhainen, K., Soininen, H., Tuomilehto, J., & Nissinen, A. (2001) · BMJ · doi:10.1136/bmj.322.7300.1447 · Cited by 1,618 · cited 4×
“Several studies reported on the effect that high levels of cholesterol had on risk [4–6].”
InfluentialObesity and Vascular Risk Factors at Midlife and the Risk of Dementia and Alzheimer Disease
Kivipelto, M., Ngandu, T., Fratiglioni, L., Viitanen, M., Kåreholt, I., Winblad, B., Helkala, E.-L., Tuomilehto, J., Soininen, H., & Nissinen, A. (2005) · Archives of Neurology · doi:10.1001/archneur.62.10.1556 · Cited by 1,291 · cited 3×
“Others reported that high total cholesterol levels increased risk significantly [6, 11, 12].”
Midlife cardiovascular risk factors and risk of dementia in late life
Whitmer, R. A., Sidney, S., Selby, J., Johnston, S. C., & Yaffe, K. (2005) · Neurology · doi:10.1212/01.wnl.0000149519.47454.f2 · Cited by 1,238 · cited 1×
“[7,8,9,10] Others reported that high total cholesterol levels increased risk significantly.[6,11,12] An additional paper from the CAIDE study also looked at high midlife cholesterol effects and reported that a high midlife total cholesterol of greater than or equal to 251 mg/dL increased risk significantly.”
The neuronal sortilin-related receptor SORL1 is genetically associated with Alzheimer disease
Rogaeva, E., Meng, Y., Lee, J. H., Gu, Y., Kawarai, T., Zou, F., Katayama, T., Baldwin, C. T., Cheng, R., Hasegawa, H., et al. (2007) · Nature Genetics · doi:10.1038/ng1943 · Cited by 1,167 · cited 3×
“It serves investigated for genetic association with AD. studies assessed only one or two variants in (http://www alzgene.org/).”
Low cholesterol stimulates the nonamyloidogenic pathway by its effect on the α-secretase ADAM 10
Kojro, E., Gimpl, G., Lammich, S., März, W., & Fahrenholz, F. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.081612998 · Cited by 804
Reiman, E. M., Chen, K., Liu, X., Bandy, D., Yu, M., Lee, W., Ayutyanont, N., Keppler, J., Reeder, S. A., Langbaum, J. B. S., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0900345106 · Cited by 785 · cited 1×
“amyloid deposition in the parenchyma and vasculature (CAA), intraneuronal accumulation of A , and low A 42 in cerebrospinal fluid (CSF) [67–70].”
Tang, M.-X. (1998) · JAMA · doi:10.1001/jama.279.10.751 · Cited by 771
Bell, R. D., Sagare, A. P., Friedman, A. E., Bedi, G. S., Holtzman, D. M., Deane, R., & Zlokovic, B. V. (2007) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/sj.jcbfm.9600419 · Cited by 670 · cited 1×
“Moreover, it may be involved in the transport of A across the BBB and in its uptake by glial cells and brain macrophages [76].”
Jones, L., Holmans, P. A., Hamshere, M. L., Harold, D., Moskvina, V., Ivanov, D., Pocklington, A., Abraham, R., Hollingworth, P., Sims, R., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0013950 · Cited by 606
GAB2 Alleles Modify Alzheimer's Risk in APOE ɛ4 Carriers
Reiman, E. M., Webster, J. A., Myers, A. J., Hardy, J., Dunckley, T., Zismann, V. L., Joshipura, K. D., Pearson, J. V., Hu-Lince, D., Huentelman, M. J., et al. (2007) · Neuron · doi:10.1016/j.neuron.2007.05.022 · Cited by 487
Wahrle, S. E., Jiang, H., Parsadanian, M., Legleiter, J., Han, X., Fryer, J. D., Kowalewski, T., & Holtzman, D. M. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m407963200 · Cited by 474
ApoE and Clusterin Cooperatively Suppress Aβ Levels and Deposition
DeMattos, R. B., Cirrito, J. R., Parsadanian, M., May, P. C., O'Dell, M. A., Taylor, J. W., Harmony, J. A. K., Aronow, B. J., Bales, K. R., Paul, S. M., et al. (2004) · Neuron · doi:10.1016/s0896-6273(03)00850-x · Cited by 459 · cited 1×
“It is involved in reverse cholesterol transport as a constituent of HDL particles [74], and additive to APOE, it also acts as an A chaperone, regulating the conversion of A to insoluble forms as well as its toxicity thereby promoting amyloid plaque formation [75].”
Cholesterol homeostasis and function in neurons of the central nervous system
Pfrieger, F. W. (2003) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-003-3018-7 · Cited by 453
Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe
Feldman, H. H., Doody, R. S., Kivipelto, M., Sparks, D. L., Waters, D. D., Jones, R. W., Schwam, E., Schindler, R., Hey-Hadavi, J., DeMicco, D. A., et al. (2010) · Neurology · doi:10.1212/wnl.0b013e3181d6476a · Cited by 438
Kalmijn, S., Foley, D., White, L., Burchfiel, C. M., Curb, J. D., Petrovitch, H., Ross, G. W., Havlik, R. J., & Launer, L. J. (2000) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.20.10.2255 · Cited by 417 · cited 2×
“[22] HAAS n= 3,734 men (251 dementia, 82 AD, 73 VaD) DSM-IIIR, NINCDS-ADRDA Tryglicerides positively associated with AD risk Mean baseline age: 53 years Mean follow-up: 25 years Kivipelto et al.”
High total cholesterol levels in late life associated with a reduced risk of dementia
Mielke, M. M., Zandi, P. P., Sjögren, M., Gustafson, D., Östling, S., Steen, B., & Skoog, I. (2005) · Neurology · doi:10.1212/01.wnl.0000161870.78572.a5 · Cited by 411
Coraci, I. S., Husemann, J., Berman, J. W., Hulette, C., Dufour, J. H., Campanella, G. K., Luster, A. D., Silverstein, S. C., & El Khoury, J. B. (2002) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64354-4 · Cited by 398
Relation of Plasma Lipids to Alzheimer Disease and Vascular Dementia
Reitz, C., Tang, M.-X., Luchsinger, J., & Mayeux, R. (2004) · Archives of Neurology · doi:10.1001/archneur.61.5.705 · Cited by 397 · cited 2×
“In contrast, three articles reported an association between higher total cholesterol levels in late life and a reduced risk of dementia [13–15].”
Self-citationHaag, M. D. M., Hofman, A., Koudstaal, P. J., Stricker, B. H. C., & Breteler, M. M. B. (2009) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2008.150433 · Cited by 393 · cited 2×
“Several well-performed, population-based observational studies [28–32] show a protective effect of statin therapy on the risk of AD and dementia, even after adjustment for demographic and vascular confounders.”
Vascular risk factors promote conversion from mild cognitive impairment to Alzheimer disease
Li, J., Wang, Y. J., Zhang, M., Xu, Z. Q., Gao, C. Y., Fang, C. Q., Yan, J. C., & Zhou, H. D. (2011) · Neurology · doi:10.1212/wnl.0b013e318217e7a4 · Cited by 367
Liu, Q., Zerbinatti, C. V., Zhang, J., Hoe, H.-S., Wang, B., Cole, S. L., Herz, J., Muglia, L., & Bu, G. (2007) · Neuron · doi:10.1016/j.neuron.2007.08.008 · Cited by 364
Lack of ABCA1 Considerably Decreases Brain ApoE Level and Increases Amyloid Deposition in APP23 Mice
Koldamova, R., Staufenbiel, M., & Lefterov, I. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m504513200 · Cited by 350 · cited 1×
“[115, 116].”
A CD36-initiated Signaling Cascade Mediates Inflammatory Effects of β-Amyloid
Moore, K. J., El Khoury, J., Medeiros, L. A., Terada, K., Geula, C., Luster, A. D., & Freeman, M. W. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m208788200 · Cited by 327 · cited 1×
“CD36 is involved in microglial binding of fibrillar A and consecutive activation of an innate immune response [142, 143].”
Deletion of Abca1 Increases Aβ Deposition in the PDAPP Transgenic Mouse Model of Alzheimer Disease
Wahrle, S. E., Jiang, H., Parsadanian, M., Hartman, R. E., Bales, K. R., Paul, S. M., & Holtzman, D. M. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m508780200 · Cited by 325 · cited 1×
“[115, 116].”
Kim, J., Castellano, J. M., Jiang, H., Basak, J. M., Parsadanian, M., Pham, V., Mason, S. M., Paul, S. M., & Holtzman, D. M. (2009) · Neuron · doi:10.1016/j.neuron.2009.11.013 · Cited by 308 · cited 1×
“Mouse experiments show that LDLR has a beneficial effect on AD pathology via enhancement of A clearance [103].”
Cholesterol for synthesis of myelin is made locally, not imported into brain
Jurevics, H., & Morell, P. (1995) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1995.64020895.x · Cited by 302
Vascular Risk Factors for Incident Alzheimer Disease and Vascular Dementia: The Cache County Study
Hayden, K. M., Zandi, P. P., Lyketsos, C. G., Khachaturian, A. S., Bastian, L. A., Charoonruk, G., Tschanz, J. T., Norton, M. C., Pieper, C. F., Munger, R. G., et al. (2006) · Alzheimer Disease & Associated Disorders · doi:10.1097/01.wad.0000213814.43047.86 · Cited by 293 · cited 1×
“Several studies reported on the effect that high levels of cholesterol had risk [4–6].”
Pravastatin and cognitive function in the elderly. Results of the PROSPER study
Trompet, S., Vliet, P., Craen, A. J. M., Jolles, J., Buckley, B. M., Murphy, M. B., Ford, I., Macfarlane, P. W., Sattar, N., Packard, C. J., et al. (2010) · Journal of Neurology · doi:10.1007/s00415-009-5271-7 · Cited by 291 · cited 1×
“However, in contrast, several controlled randomized trials exploring the effect of statin on progression of AD have found no benefit.[33,34,35,36,37,38] One explanation for the dramatic differences between observational studies and clinical trials may be that treatment trials tend to be short term and include patients…”
Bryleva, E. Y., Rogers, M. A., Chang, C. C. Y., Buen, F., Harris, B. T., Rousselet, E., Seidah, N. G., Oddo, S., LaFerla, F. M., Spencer, T. A., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0913828107 · Cited by 209
A summary risk score for the prediction of Alzheimer disease in elderly persons
Reitz, C., Tang, M.-X., Schupf, N., Manly, J. J., Mayeux, R., & Luchsinger, J. A. (2010) · Archives of Neurology · doi:10.1001/archneurol.2010.136 · Cited by 199 · cited 1×
“[174–178] Third, the available data relating the various lipid types (LDL-C, HDL-C, triglycerides) with AD is still insufficient.”
Self-citationKim, W. S., Rahmanto, A. S., Kamili, A., Rye, K.-A., Guillemin, G. J., Gelissen, I. C., Jessup, W., Hill, A. F., & Garner, B. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m607831200 · Cited by 191 · cited 1×
“Partly conflicting effects of ABCG1 on A PP metabolism have been observed in vitro [128, 129].”
Accelerated decline in apolipoprotein E-ϵ4 homozygotes with Alzheimer's disease
Craft, S., Teri, L., Edland, S. D., Kukull, W. A., Schellenberg, G., McCormick, W. C., Bowen, J. D., & Larson, E. B. (1998) · Neurology · doi:10.1212/wnl.51.1.149 · Cited by 152 · cited 1×
“amyloid deposition in the parenchyma and vasculature (CAA), intraneuronal accumulation of A , and low A 42 in cerebrospinal fluid (CSF) [67–70].”
Apolipoprotein E Genetic Variation and Alzheimer’s Disease
Rubinsztein, D. C., & Easton, D. F. (1999) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000017120 · Cited by 151 · cited 1×
“free of AD well into their 80s [63, 66].”
Koldamova, R. P., Lefterov, I. M., Lefterova, M. I., & Lazo, J. S. (2001) · Biochemistry · doi:10.1021/bi002186k · Cited by 131 · cited 1×
“APOA1 inhibits the aggregation and toxicity of A in vitro [132].”
Accumulation of intraneuronal Aβ correlates with ApoE4 genotype
Christensen, D. Z., Schneider-Axmann, T., Lucassen, P. J., Bayer, T. A., & Wirths, O. (2010) · Acta Neuropathologica · doi:10.1007/s00401-010-0666-1 · Cited by 120
Increased caveolin-1 expression in Alzheimer’s disease brain
Gaudreault, S. B., Dea, D., & Poirier, J. (2004) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2003.07.004 · Cited by 120
Cuenco, K. T. (2008) · Archives of Neurology · doi:10.1001/archneur.65.12.1640 · Cited by 61
Zou, F., Gopalraj, R. K., Lok, J., Zhu, H., Ling, I.-F., Simpson, J. F., Tucker, H. M., Kelly, J. F., Younkin, S. G., Dickson, D. W., et al. (2007) · Human Molecular Genetics · doi:10.1093/hmg/ddm365 · Cited by 58
Expression of SORL1 and a novel SORL1 splice variant in normal and Alzheimers disease brain
Grear, K. E., Ling, I.-F., Simpson, J. F., Furman, J. L., Simmons, C. R., Peterson, S. L., Schmitt, F. A., Markesbery, W. R., Liu, Q., Crook, J. E., et al. (2009) · Molecular Neurodegeneration · doi:10.1186/1750-1326-4-46 · Cited by 56 · cited 1×
“[80,81,82,83,84,85,86,87,88,89,90,91,92,93,94,95,96,97] The haplotypes were further Reitz Page 6”
Fagan, A. M., Christopher, E., Taylor, J. W., Parsadanian, M., Spinner, M., Watson, M., Fryer, J. D., Wahrle, S., Bales, K. R., Paul, S. M., et al. (2004) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63399-8 · Cited by 54 · cited 1×
“However, amyloid pathology is unaltered in APOA1-deficient A PP-transgenic mice [133].”
Genetic association of low density lipoprotein receptor and Alzheimer's disease
Gopalraj, R. K., Zhu, H., Kelly, J. F., Mendiondo, M., Pulliam, J. F., Bennett, D. A., & Estus, S. (2005) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2004.09.001 · Cited by 51
Functional interaction between APOE4 and LDL receptor isoforms in Alzheimer's disease
Cheng, D., Huang, R., Lanham, I. S., Cathcart, H. M., Howard, M., Corder, E. H., & Poduslo, S. E. (2005) · Journal of Medical Genetics · doi:10.1136/jmg.2004.024968 · Cited by 33
Cited by
Biessels, G. J., Strachan, M. W. J., Visseren, F. L. J., Kappelle, L. J., & Whitmer, R. A. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(13)70088-3 · Cited by 551
Involvement of Lipids in Alzheimer’s Disease Pathology and Potential Therapies
Chew, H., Solomon, V. A., & Fonteh, A. N. (2020) · Frontiers in Physiology · doi:10.3389/fphys.2020.00598 · Cited by 353
“HDL-C is often referred to as “good cholesterol,” has beneficial antioxidant and anti-inflammatory effects in the body, and has been observed to modulate ß-amyloid (Aß) production in the brain, a key biomarker of AD pathogenesis (Reitz, 2012; Hottman et al., 2014).”
BackgroundRegulation of beta-amyloid production in neurons by astrocyte-derived cholesterol
Wang, H., Kulas, J. A., Wang, C., Holtzman, D. M., Ferris, H. A., & Hansen, S. B. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2102191118 · Cited by 301
Associations Between Serum Cholesterol Levels and Cerebral Amyloidosis
Reed, B., Villeneuve, S., Mack, W., DeCarli, C., Chui, H. C., & Jagust, W. (2014) · JAMA Neurology · doi:10.1001/jamaneurol.2013.5390 · Cited by 267
Parial, L. L., Lam, S. C., Ho, J. Y. S., Suen, L. K. P., & Leung, A. Y. M. (2021) · Aging & Mental Health · doi:10.1080/13607863.2020.1786801 · Cited by 43
Metadata
- Authors
- Reitz, C.
- Venue
- Journal of Alzheimer's Disease
- Publisher
- SAGE Publications
- Published
- 2012-06-08
- Volume
- 30
- Issue
- s2
- Pages
- S127-S145
- ISSN
- 1387-2877 (ISSN-L)
- 1875-8908
- OpenAlex
- W114449514
- Cited by
- 75
- References
- 46
- FWCI
- 2.83
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.